A state-of-the-art spinout business, 4D Medicine, has been developed by the Universities of Warwick and Birmingham to market a new class of materials including liquid resins that can be assembled into secure 3D scaffolds to help patients heal faster from major medical procedures.
The company has received two hundred and eighty-one thousand pounds of pre-seed investment from SFC Capital, and one hundred and ninety-seven thousand pounds of funding from Innovate UK to build a range of implantable medical devices that will enhance the quality of life of a patient by improving recovery and healing after standard surgical procedures.
“4D Medicine has been developed by the Universities of Warwick and Birmingham to market new materials.“
The polycarbonate resins, developed by Dr Andrew Weems and Professor Andrew Dove, University School of Chemistry, are novel bioresorbable materials with tuneable engineering and chemical properties, powerful shape memory and encouraging performance in tissue healing. The composition of the novel resins is covered as part of the spinout procedure by a family of patients submitted by the Universities of Warwick and Birmingham, who were recently licenced to 4D Medicine Ltd.
4D Medicine, trading as 4D Biomaterials, will be led by CEO Philip Smith, who is a university start-up specialist with a history in polymeric products, raising early-stage funding for development ventures and rising production.
The company will concentrate on expanding its products processing and selling capabilities and initial implementations, including options for a new lumpectomy product to meet the needs of emerging demand for patients who have experienced a surgical procedure that is used in the early stages of breast cancer diagnosis, as well as a first care alternative for women.
Smith stated: “The anticipated benefits of our lumpectomy device concept include filling the void left by surgery and promoting faster healing by encouraging the healthy tissue to grow back through the 3-D printed scaffold. In the current difficult environment, we are very pleased to have raised pre-seed investment with support from University of Birmingham Enterprise. This important funding milestone reflects our growing confidence in the clinical and commercial potential of our products and technology.”
Lead Investment Manager, SFC Capital, Rohallah Ghasemi, stated: “4D Medicine’s science is fully developed and has been externally validated and at the time of our investment, its team of field experts had clearly shown evidence of commercial demand. The potential target markets are huge and we believe 4D’s technology will be a game changer in the biomaterials market. We are very pleased to have led their pre-seed round earlier this year.”See all the latest jobs in Medical Devices